Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16421615 | 0.79 | MVD (0.41) | DPP4SPHK1MVD | |
| SCHEMBL12949889 | 0.79 | DPP4 (0.56) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL21430566 | 0.79 | DPP4 (0.56) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL10421372 | 0.79 | DPP4 (0.56) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL19658205 | 0.76 | SPHK1 (0.38) | SPHK1POLBL3MBTL1 | |
| SCHEMBL25095633 | 0.74 | STAT6 (0.36) | DPP4DPP8FAPDPP9DPP7 | |
| SCHEMBL14273591 | 0.72 | DPP4 (0.41) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL4589694 | 0.72 | POLB (0.37) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL12324861 | 0.72 | DPP4 (0.41) | DPP4DPP8FAPDPP9PREP | |
| SCHEMBL19696569 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840537-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170044214-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044214-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | SLC7A1, SLC47A1, SLC47A2 | DPP4 3161/4885DPP8 1778/4885FAP 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.